Abstract 225P
Background
Prostate cancer ranges from indolent to aggressive, with 10–20% of patients developing metastases. Immune cell interactions in the tumor microenvironment facilitate growth. This study aimed to characterize circulating immune cells in patients with oligometastatic (OMPC) and plurimetastatic prostate cancer (PMPC).
Methods
This retrospective cohort study included individuals with metastatic prostate cancer (mPC). Patients were classified into two groups: OMPC (five or fewer lesions in bone and/or lymph nodes via CT or bone scans), and PMPC, those not meeting OMPC criteria. Demographic data and immune cell subsets were collected at admission. After blood collection, peripheral blood mononuclear cells were isolated, and flow cytometry assessed various immune populations (γδ T cells, αβ T cells, Tregs, memory T cells, effector T cells, NK cells, NKT cells, B cells, myeloid cells, and monocytes) and cytokines (TNF-α, IFN-γ, IL-17). The Mann–Whitney U test was used for comparisons, with p ≤ 0.05 considered significant.
Results
43 patients were identified, with a median age of 64 years (50-80). 17 patients (39.5%) had OMPC and 26 (60.5%) had PMPC. 16 patients (37.2%) presented with de novo mPC. Bone was the most common metastatic site in both groups. Most patients (67.4%, n=29) received hormone therapy (HT) as first-line treatment , while 9 patients (20.9%) received chemotherapy plus HT. An increase in γδ2+ T cells (p=0.048) was noted in the OMPC group. There was a trend toward increased levels of γδ2+ expressing IFN-γ (p=0.066) in PMPC patients.
Conclusions
A significant increase in γδ2+ T cells was observed in OMPC. These cells are critical for immune modulation. Elevated levels in OMPC subgroup may indicate an active immune response, potentially providing a protective effect against tumor progression in this subgroup. Conversely, PMPC patients showed a trend toward increased IFN-γ expression in γδ2+ T cells (p=0.066). While these cells can produce IFN-γ, those in OMPC may be less activated, limiting their effectiveness and suggesting an immune escape mechanism. This study has limitations; results are exploratory and require confirmation in a larger cohort. We plan to validate the differences in γδ2+ T cells and IFN-γ expression in an independent group.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session